<DOC>
	<DOCNO>NCT00539838</DOCNO>
	<brief_summary>This Phase III , randomize , double blind , placebo-controlled , multicenter , parallel-group study evaluate efficacy safety ocrelizumab compare placebo combine single stable background immunosuppressive medication corticosteroid regimen patient moderately severely active systemic lupus erythematosus , moderate severe glomerulonephritis .</brief_summary>
	<brief_title>A Study Evaluate Two Doses Ocrelizumab Patients With Active Systemic Lupus Erythematosus ( BEGIN )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age 16 year time screen Diagnosis SLE Active disease screen Presence active moderate severe glomerulonephritis Currently active retinitis , poorly control seizure disorder , acute confusional state , myelitis , stroke stroke syndrome , cerebellar ataxia , dementia Lack peripheral venous access Pregnancy breast feed mother History severe allergic anaphylactic reaction humanize , chimeric murine monoclonal antibody i.v . immunoglobulin Known severe chronic pulmonary disease Evidence significant uncontrolled concomitant disease organ system related SLE , , investigator 's opinion , would impair patient participation Concomitant condition require treatment systemic corticosteroid ( exclude topical inhale ) time 52 week prior screen Known HIV chronic active Hepatitis B chronic active Hepatitis C infection Known active infection kind ( exclude fungal infection nail bed oral thrush resolve Day 1 ) within 30 day prior Day 1 . In addition , major episode infection require hospitalization treatment intravenous antiinfectives 30 day prior Day 1 oral antiinfectives 14 day prior Day 1 History serious recurrent chronic infection History cancer ( except basal cell carcinoma skin excise cure ) History alcohol drug abuse 52 week prior screen Major surgery 4 week prior screen exclude diagnostic surgery Previous treatment CAMPATH1H Previous treatment BAFF direct treatment 12 month prior screen Previous treatment Bcell target therapy one direct BAFF Treatment investigational agent , , 28 day prior screen five halflives investigational drug ( whichever longer ) Receipt live vaccine 6 week prior Day 1 Intolerance contraindication oral i.v . corticosteroid Treatment second immunosuppressive immunomodulatory drug 8 week prior Day 1 Prednisone dose â‰¥ 0.7 mg/kg/day ( equivalent ) &gt; 7 previous 30 day prior screen Treatment cyclophosphamide calcineurin inhibitor 12 week prior screen Positive hepatitis BsAg hepatitis C serology . Patients HBsAg negative HBcAb positive may enrol negative DNA test</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>SLE</keyword>
</DOC>